Remiges Ventures
2023.08.25Remiges’ portfolio company Phost’in Therapeutics SAS and Taiho Pharmaceuticals have announced an Option and License Agreement on the First-in-Class GnT-V inhibitor PhOx430
2023.07.28Restore Vision, Inc., one of our portfolio companies, was selected for AMED Strengthening Program for Pharmaceutical Venture Ecosystem
2023.06.05Remiges Ventures led the 1st close of Series A round for Restore Vision, Inc. in Japan
2023.03.31Capacity Bio, For Which Remiges Ventures Was Founding Investor, Raised $35M
2023.01.04Remiges Portfolio Companies Raised In Aggregate More Than $145 million in 2022
